Lydia Usha, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Hereditary inflammatory breast cancer associated with BRCA2 mutation: a rare disease presentation in mother and daughter.
   Jimenez AM, Growney A, Behrens G, Corbridge C, Chapman DD, Usha L.
   Clin Adv Hematol Oncol. 2012
   2012 Jun
   10(6):402-4. No abstract available.
   
2. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
   Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L.
   J Transl Med. 2012
   2012 Apr 27
   10:79. doi: 10.1186/1479-5876-10-79.
   
3. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
   Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.
   Gynecol Oncol.
   2011 Jun 1
   121(3):455-61
   
4. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts
   Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS
   J Hematol Oncol
   2008 Aug 14
   1:12
   

• To watch a brief video of Lydia Usha, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• Cancer research was the reason that brought me to an academic institution — the ability to treat cancer patients and to do cancer research. That’s why I’m here.

  Many people think that oncology could be depressing. I think it’s the other way around. I think it’s very rewarding. And what is rewarding for me is that I am with my patients in the often critical times of their lives. We have a very deep relationship and a deep bond that gives me that profound sense of satisfaction and the feeling that I’ve done everything possible.